You are here: Industry Insights > Bayer

News List

Bayer, its consumer health ambitions snagged, recruits Nestle executive to replace current chief fiercepharma
November 16, 2017
The current head of the division, Erica Mann, will step aside at the end of March—a full nine months before her contract was scheduled to run out—and a Nestle executive will step in to replace her.
Bayer pays $400M upfront to buy into Loxo cancer drugs fiercebiotech
November 15, 2017
Bayer has paid $400 million (€340 million) and committed to more than $1 billion more to buy into Loxo Oncology’s tropomyosin receptor kinase (TRK) inhibitor franchise.
Bayer, Loxo Oncology to Develop, Commercialize Therapies for Genetic Drivers of Cancer americanpharmaceuticacreview
November 15, 2017
Bayer has entered into an exclusive global collaboration with Loxo Oncology for the development and commercialization of larotrectinib (LOXO-101) and LOXO-195.
Bayer, Loxo Partner Up For $1.5B Cancer Drug Development pharmamanufacturing
November 15, 2017
Bayer and Loxo Oncology have announced plans to work together to develop and commercialize two cancer therapies in a deal that potentially brings Loxo up to $1.55 billion over the coming few years.
NICE shoots down Bayer's Stivarga in liver cancer, citing price, clinical questions fiercepharma
November 09, 2017
Bayer is working to position Stivarga as part of a treatment regimen for those who have failed on its first-line liver cancer fighter, Nexavar. But that’s not going to work in England. At least, not yet.
Bayer’s Stivarga rejected by NICE for liver cancer pharmatimes
November 09, 2017
Bayer’s Stivarga is not being recommended by NHS treatment cost regulators for certain patients with advanced unresectable hepatocellular carcinoma.
Bayer files low-dose Xarelto/aspirin combo pharmatimes
November 08, 2017
Bayer is seeking permission to market in Europe its bloodthinner Xarelto in combination with aspirin to reduce the risk of cardiovascular events in patients with coronary or peripheral artery disease.
Bayer files long-acting haemophilia therapy in the US pharmatimes
November 01, 2017
US regulators are reviewing Bayer’s BAY94-9027, a longer-acting Factor VIII therapy designed to reduce the number of infusions necessary to prevent bleeds in patients with Haemophilia A.
Bayer NAVIGATE ESUS study stopped early due to little chance to achieve overall benefit pharmaasia
October 17, 2017
The Bayer Phase III NAVIGATE ESUS study was evaluating rivaroxaban vs aspirin in patients with embolic stroke of undetermined source (ESUS).
NICE backing for Bayer’s Stivarga in GIST pharmatimes
October 13, 2017
Bayer’s Stivarga is being backed by the National Institute for Health and Care Excellence as a cost-effective option for the treatment of adults with gastrointestinal stromal tumours (GIST).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page